Company intelligence / Profile preview

VIVES Partners

Louvain-la-Neuve, Wallonia, Belgium

Ownership: Private
Employees: ~25
Development stage: Other

Overview

VIVES Partners is an early-stage, multisectoral investment fund based in Belgium, specializing in spin-offs from UCLouvain and neighboring universities, including biotech and healthcare startups. It has transformed cutting-edge academic research into commercial ventures through strategic creation and growth, including helping launch The Akkermansia Company (acquired by Danone in 2025) and investing in Nuclidium and Eligo Bioscience, among others.

Industry: Investors

Partnerships

SeventureInnovation IndustriesWallonie EntreprendreDanone

Beyond the preview

Go deeper on VIVES Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIVES Partners.

Explore the full profile